Multiple Sclerosis Drugs Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 To 2030

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system. It is the most common neurological disease in adults and women. The global multiple sclerosis drugs market is rapidly growing due to factors such as growing prevalence of MS, significant unmet needs, and promising pipeline molecules.

The report titled Multiple Sclerosis Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 -2030 offers strategic insights into the overall multiple sclerosis drugs market along with the market size and estimates for the duration 2020 to 2030. The research study covers in-depth analysis of market segments based on molecule type (biologics and small molecules), route of administration (oral therapeutic drugs, parenteral therapeutic drugs) and different geographical regions.

Along with quantitative information, qualitative information sets and assessment tools are provided in this study for better analysis of the overall market scenario, pipeline analysis and future prospects. Information such as market inclination insights and drivers, challenges and opportunities assists the readers for understanding the ongoing trends in the global multiple sclerosis drugs market. Tools such as market positioning of key players and attractive investment proposition provide the readers with insights on the competitive scenario of the global multiple sclerosis drugs market. This report concludes with company profiles section that highlights major information about the key players engaged in global multiple sclerosis drugs market. In-depth competitive environment analysis and historical years (2015) market size data are also provided in the report.

Multiple sclerosis (MS) is an autoimmune disease in which the myelin sheath of nerve cells in the brain and spinal cord are damaged. MS organizations have estimated that 2.3 million people are living with the disease worldwide. There is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. For the purpose of the study market is segmented on the basis of molecule type such as biologics and small molecules. It is observed that, in the base year 2016, biologics was major revenue generating segment. Biologics such as Avonex, Betaseron, CinnoVex, Extavia, Rebif, and Tysabri are widely used in the market. However, it is estimated that small molecule segment will show highest growth during forecast period due to the expected launch of various oral formulations of small molecules such as ALKS-8700, OS-440, RPC-1063, ACT-128800 and BAF312.

Multiple sclerosis (MS) is a chronic demyelinating inflammatory disease of the central nervous system, it is a most common neurological disease of adults age between 20-40, affecting over 450,000 patients in the United States and over 3.5 million patients worldwide. Currently, there is no cure for MS but various disease management options are available in market. These medications are used to slow disease progression and lower relapse rate. It is observed that in the base year 2016, parenteral therapeutic drugs were major revenue generating segment because some major parenteral drugs such as Avonex, Betaseron, Copaxone, Extavia, Glatopa, Plegridy, Rebif, Zinbryta are driving the market growth. However, it is estimated that oral therapeutics drugs will show significant market growth during forecast period due to the expected launch of oral pipeline molecule such as OS-440, MD1003, Cladribine, CS-0777, Gilenya, RPC-1063, RPC-1063 and ACT-128800.

In the base year 2021, North America dominated the multiple sclerosis drugs market and it is estimated to show fastest market growth during forecast period. Some factors such as increasing incidence of MS, technological advances, upsurge in funding by government agencies and private organizations in healthcare system and higher cost of treatment medication are prime factors that fueling the growth of multiple sclerosis drugs market in North America. According to the Multiple Sclerosis Foundation, more than 400,000 people in the United States and about 2.5 million people around the world have MS; about 200 new cases are diagnosed each week in the United States. MS is an expensive disease to treat; it is studied that direct and indirect health care costs range from US$ 8,528 to US$ 54,244 per patient per year in the United States. Europe is the second largest revenue generating regional market for multiple sclerosis. Existence of higher number of target population is driving the market growth in Europe. The Multiple Sclerosis Foundation estimates that the incidence of MS is higher in colder climates, people of Northern European descent have the highest risk of developing MS, no matter where they live.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Multiple Sclerosis Drugs market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Multiple Sclerosis Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Molecule

• Biologics
• Small Molecules

Route of Administration

• Oral Therapeutic Drugs
• Parenteral Therapeutic Drugs

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Multiple Sclerosis Drugs market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2030.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Multiple Sclerosis Drugs market?
• Which is the largest regional market for Multiple Sclerosis Drugs market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Multiple Sclerosis Drugs market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Multiple Sclerosis Drugs market worldwide?

This product will be delivered within 2 business days.